Your browser doesn't support javascript.
loading
Immunomodulatory therapy using a pediatric dialysis system ameliorates septic shock in miniature pigs.
Johnston, Kimberly A; Pino, Christopher J; Chan, Goldia; Ketteler, Skylar K; Goldstein, Stuart L; Humes, H David.
Afiliación
  • Johnston KA; Division of Nephrology, Department of Internal Medicine, University of Michigan Ann Arbor, Ann Arbor, MI, USA.
  • Pino CJ; Innovative Biotherapies, Ann Arbor, MI, USA.
  • Chan G; Division of Nephrology, Department of Internal Medicine, University of Michigan Ann Arbor, Ann Arbor, MI, USA.
  • Ketteler SK; Innovative Biotherapies, Ann Arbor, MI, USA.
  • Goldstein SL; Unit for Laboratory Animal Medicine, University of Michigan Ann Arbor, Ann Arbor, MI, USA.
  • Humes HD; Division of Nephrology, Department of Internal Medicine, University of Michigan Ann Arbor, Ann Arbor, MI, USA.
Pediatr Res ; 93(1): 89-96, 2023 01.
Article en En | MEDLINE | ID: mdl-35501373
BACKGROUND: Application of the immunomodulatory selective cytopheretic device (SCD) to enhance renal replacement therapy and improve outcomes of acute kidney injury in pediatric patients is impeded by safety concerns. Therapy using a pediatric hemodialysis system could overcome these limitations. METHODS: Yucatan minipigs (8-15 kg) with induced septic shock underwent continuous hemodiafiltration with the CARPEDIEM™ pediatric hemodialysis system using regional citrate anticoagulation (RCA) with or without SCD (n = 5 per group). Circuit function plus hemodynamic and hematologic parameters were assessed for 6 h. RESULTS: SCD was readily integrated into the CARPEDIEM™ system and treatment delivered for 6 h without interference with pump operation. SCD-treated pigs maintained higher blood pressure (p = 0.009) commensurate with lesser degree of lactic acidosis (p = 0.008) compared to pigs only receiving hemodiafiltration. Renal failure occurred in untreated pigs while urine output was sustained with SCD therapy. Neutrophil activation levels and ss-SOFA scores at 6 h trended lower in the SCD-treated cohort. CONCLUSIONS: SCD therapy under RCA was safely administered using the CARPEDIEM™ pediatric hemodialysis system for up to 6 h and no circuit compatibility issues were identified. Sepsis progression and organ dysfunction was diminished with SCD treatment in this model supportive of therapeutic benefit of this immunomodulatory therapy. IMPACT: SCD therapy with regional citrate anticoagulation has the potential to be administered safely to patients weighing <20 kg using the Carpediem renal replacement therapy platform. Use of a renal replacement therapy platform designed specifically for neonates/infants overcomes safety concerns for delivery of SCD treatment in this population. SCD therapy using the Carpediem renal replacement therapy platform retained the suggestive efficacy seen in larger children and adults to reduce organ injury and dysfunction from sepsis.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Choque Séptico / Sepsis / Lesión Renal Aguda Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Pediatr Res Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Choque Séptico / Sepsis / Lesión Renal Aguda Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Pediatr Res Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos